MASKS

Everyone was talking about masks.

No one was talking about what happened when systems stopped working all at once — supply chains, approvals, timelines, assumptions.

Cloth masks. Surgical masks. Bandanas. Anything that could sit between a mouth and the air. The question everywhere was how not to catch the virus.

I said it out loud one afternoon. "Can't we do something with this?"

Don didn't answer immediately. I could see him considering. "What are you thinking?" I said.

"A mask," he said. "Something wearable. Something that doesn't just block, but actually deactivates what passes through."

He expanded it without enthusiasm or caution—just logic. Instead of relying on governments to sanitize environments after the fact, a person should be able to protect themselves. Or, if they were sick, protect others. Not filtration. Not dilution.

A UVC-LED mask.

Don had been working in light-based technologies for decades—long before ultraviolet became shorthand for sanitation. His patents, covering a UVC-LED method for deactivating contagions, already existed. They had been filed decades earlier, at a time when the technology still needed to catch up to the idea. Don had always worked that way—thinking years ahead of what was technically possible.

He paused.

"Lisa," he said finally, "this isn't a prototype you build in your garage."

He broke it down the way he always did—plainly.

Using UVC-LED light near the human body wasn't something you rushed. What made it complicated wasn't the idea. It was scale. Safety. Consistency. Quality control. Light behaves differently depending on distance, exposure, containment. One error and the entire concept failed.

"To do this properly," he said, "you'd need partners at the highest level. Companies like Signify—Philips. AMS-Osram. LG Electronics. Possibly governments. This takes years."

Even with legacy patents, nothing moved without validation.

An airline wouldn't install UVC systems into cabins or ventila-tion without exhaustive testing. Neither would hospitals. Or schools. Or public transit. You don't introduce light-based eradication tech-nology into environments filled with people unless you can prove—again and again—that it behaves exactly as intended.

"It's not just design," Don said. "It's manufacturing discipline.

Repeatability. Failure tolerance. One inconsistency and it's dead." I understood that.

I looked at him.

"But maybe if we can show proof of concept," I said, "we get people on board."

Don considered that.

"If you want to do it," he said, "let's do it." But I also understood timing.

By 2020, the world had settled on filtration. Ventilation. Airflow. The strategy was mitigation—reduce viral load, keep systems running. Fit solutions into existing infrastructure.

What Don's work proposed was different. Not filtering the problem.

Eliminating it.

That distinction mattered. And it made people cautious.

I didn't have an unlimited budget. I was funding the work myself. I didn't have a lab down the hall or a manufacturing floor to lean on. What I did have was access—to people who knew how to build pieces of things that didn't yet exist as products.

So I assembled what I could.

Engineers. 3D modelers. Graphic designers. Sweden. Ukraine. England. Italy. India.

People who could work asynchronously. Quietly. Precisely. Pieces moving while the world was still deciding what to do.

We explored concepts for a UVC-LED mask. Wearable form factors. Internal airflow paths. Light placement. Shielding. Simula-tions. What exposure thresholds would have to be met before anyone would even consider testing it in real environments.

Nothing moved fast. That wasn't the point.

The work advanced in layers—assumptions tested, models adjusted, limits clarified. Each step answered one question and raised another.

Interest existed. Conversations happened.

But the world was already choosing a different path. Filtration fit existing systems.

Eradication required new ones.

I understood why institutions hesitated. Still, the question stayed with me.

Not whether it would be adopted. But whether it was worth proving. That answer came later.

At the time, the work continued—carefully, deliberately—

waiting to see whether the world would ever be ready for something that didn't just reduce risk, but removed it.

EXPOSURE

September 2022

In September, a friend of ours was holding an auction.

Don and I thought, why not. Marion stayed home. She said she'd gone to enough of them with Don in New York. I didn't argue.

When we arrived, the room was packed. Not busy. Packed.

People shoulder to shoulder. Voices overlapping. No distance.

No hesitation. I thought, This is not good. Superspreader event.

I didn't say it out loud, but I knew. That night, the owner called.

Two of her staff members had tested positive for COVID. She'd made an appointment to receive the monoclonal antibody injections and said we should do the same.

I called Don and Marion immediately.

It wasn't a vaccine. It was an antibody treatment for people who had been exposed. The goal wasn't prevention. It was interruption.

I went because I had been exposed.

By then, exposure alone was enough to trigger a sequence of events. There was no debate about whether to act — only how quickly.

Everything began online.

A county website. A form. Dates. Proximity. Symptoms. Drop-down menus flattening something personal into checkboxes. I filled it out carefully, knowing precision mattered. When I hit submit, I didn't feel relief. Just acknowledgment. Instructions followed. A time. A location.

West Palm Beach.

The site was inside a gym.

Not a hospital. Not a clinic. A gym. High ceilings. Bright light.

The basketball court had been cleared and rebuilt into order.

Stations. Row after row. Chairs. Small tables. Supplies arranged with precision.

I followed the flow.

There was no waiting-room conversation. No sense of sequence. I wasn't called by name. I realized it was my turn because suddenly I wasn't waiting anymore.

I was guided to a station and told to sit.

They explained the medication would be administered by injec-tion rather than infusion. Faster this way. No IV. Four injections, given one after another.

I nodded. I wasn't there to ask questions.

The shots were methodical, all in my leg. Calm hands, practiced movement. I focused on staying still. On breathing. On not antici-pating the next one before it happened.

Around me, the gym absorbed everything. Sound didn't carry. Other stations mirrored the same process — people separated by distance but linked by circumstance, each contained within their own measured square of space.

When it was finished, I was directed to wait. Observation.

Chairs spaced far apart, all facing the same direction. No talk-ing. No reason to look at one another. Fifteen minutes measured not by a clock, but by awareness — of breath, of sensation, of the body adjusting.

I don't remember anyone telling me it was over. I remember realizing I could leave.

I walked back through the gym, past stations already reset for the next round. Outside, the Florida sun felt intrusive after the controlled brightness inside. I sat in my car for a moment before starting the engine.

What stayed with me wasn't fear.

It was how efficiently something so personal had been handled. How a global emergency had been translated into process. How

four injections in a gym could happen without ceremony — and still matter.

That was September.

Wide rooms. Measured distance. Important things done quickly. And then, waiting to see what came next.

Red Tape

It took over a year to get what I thought would be straight-forward.

Proof of concept.

We had filed patents. Done the conceptualization. Run computer simulations for airflow, UVC irradiation, exposure time. We had 3D-printed prototypes fitted with LEDs.

The computer simulations worked. We did it.

I called Don.

"We got it," I said. "The numbers work. The mask will work." There was exhilaration. A real breakthrough.

To get attention, I needed live virus testing.

But filtration was still the only conversation anyone wanted to have.

The question wasn't whether it would work. The question was how to prove it.

U.S. labs were bound by bureaucracy. Access to live COVID samples was restricted. Specialized biosafety facilities were over-booked. Even if I could navigate the regulatory hurdles, the process would take months—maybe years. Everything moved through chan-nels that didn't move.

By then, I was already rationing myself. Calls instead of meet-ings. Emails instead of calls. Conversations ended early, not because the work was done, but because my breath was. I didn't announce it. I adjusted and kept going.

I called a U.S. lab.

Press 1 for administration. Press 3 for research inquiries. Wait.

Transfer. Wait again.

It took hours to reach someone who could make decisions.

When I finally did, they had their priorities. I went back to the computer simulations.

There has to be a lab that wants to do this, I thought. That wants to say they tested it first.

I called one of the engineers.

"This is a feather in everyone's cap," I said. He paused.

"I'm Ukrainian," he said. "I have a friend who works at the D.K. Zabolotny Institute. I can try to get an introduction to the director." The Institute had been around since 1928. Founded by Danylo Zabolotny, a world-renowned microbiologist. It was the oldest and most respected research center in Ukraine for microbiology and

virology. They had the expertise. And they had access to live virus. "If they can't do it," I said, "ask if they know someone who

can."

A few days later, he called back. They would do it.

First clinical testing of our working prototypes. But we had to provide the testing platform.

There was one constraint. The lab couldn't access live COVID virus—too many regulations, even for an institute of their caliber. But they could test with H1N1.

That was sufficient.

UVC light doesn't discriminate by strain. If the mask deacti-vated H1N1 under normal breathing conditions, the mechanism worked. It would work on any virus.

Roman said, "Lisa, what do you think—what if I 3D-print the platform?"

"Do it," I said.

The platform had to be airtight. Precise. It took time to get right. Then it had to be tested. And retested.

Two months passed.

The rig was still being tested.

Russia was sending more soldiers to the Ukrainian border.

Thousands. Tanks. Artillery. The language was escalating.

I kept watching the news.

This wasn't a march at the border. This wasn't posturing. Were they watching the same news?

I called Roman.

"We have to get them to start testing. Russia and Ukraine—it's all over the news."

On a conference call, Dr. Svitlana Zagorodnya reassured me. "We'll start in a few days," she said. "Don't worry. The Russians

always do this. They send troops for show." The next day, the war broke out.

Proof of Concept

Weeks passed.

I kept sending emails. Short messages. Checking in. Asking if anyone was safe.

Nothing came back.

The news showed cities under siege. Infrastructure collapsing. People fleeing west. I didn't know if the lab still existed. I didn't know if the staff were alive. The work—carefully planned, contrac-tually defined—had dissolved into silence.

At that point, "work" didn't mean progress. It meant staying ready without knowing if there would ever be a next step.

I waited.

I called Roman.

"I hope to hear from someone soon," I said. "I don't want to take the contract away from them, but we need to get the testing done."

"I know," he said. More waiting.

In May, Svitlana finally wrote back.

We had started with Dear Dr. Zagorodnya. By then, it was just Svitlana.

They were restarting the work. The team had survived. The platform and the working prototypes had not.

They had been destroyed during the invasion.

Air raids were constant. There was no work happening yet—only survival. Everything else had been suspended.

She asked that we build another platform. More working proto-types. And get them into Ukraine.

I called Roman.

"I can build the platform and the prototypes," he said. Then he paused.

"The next part," he said, "I need your permission."

He explained it plainly. The platform couldn't be shipped. It couldn't be declared. Anything official would be delayed, seized, or turned back. To cross the border, it would have to be invisible.

"I can build it in sections," he said. "Disassemblable. It will weigh more, but it can be carried. Reassembled on the other side."

"And how do we get it there?" I asked.

"I'll send it to Poland," he said. "My family will pick it up. My cousin will drive it over the mountains into Ukraine. He'll take the backroads. Then cross the border on foot. It's the only way."

"So we're smuggling it in," I said. "Yes," he said. "That's the only way." "Okay," I said. "Do it."

So we waited again.

A few weeks later, I got a text. Glory to Ukraine.

"The platform is ready," Roman wrote. "And so are the masks." Then the updates began.

Brief texts. Short calls. The package had reached Poland. His family had it. They were crossing the border.

Then—nothing. No texts. No calls. For two days.

I didn't follow up. I waited.

On the third day, my phone rang. Svitlana had the package.

They would begin testing.

The plan was careful and exact. First, they would test the device

to ensure it wasn't leaking. If it passed, laboratory testing would begin—two weeks. A report expected by late July.

That was the plan.

But nothing moved in straight lines anymore.

Every time Roman called, I wondered if something had happened. The work was stop-and-start. Air raids. Power interrup-tions. Resource shortages. Progress measured in windows between sirens.

That was how logistics worked now.

Not through shipping companies. Not through couriers. Through families. Through borders crossed quietly.

In August, the testing was completed. It worked.

The UVC-LED mask irradiated and inactivated viral and bacte-rial particles during breathing.

The agreement with the D.K. Zabolotny Institute of Microbi-ology and Virology—signed back in November 2021—had finally reached its purpose.

Against timelines that had collapsed. Against distance. Against a war.

The proof existed.

Not because conditions were ideal.

But because people kept working— and because everyone, at some point, was willing to wait.

No Takers

By the time the testing was complete, I wasn't just tired. I had been tired for a long time.

I had done the work while sick. I had kept going as my body became less predictable, less forgiving. I told myself it was tempo-rary. That once there was an answer—once there was proof—I could stop.

We proved it.

The mask worked.

The data was real. The mechanism held. The question had been answered.

And then nothing happened.

Don and I had both invested significant money. I had taken a real financial gamble—though at first it didn't seem like one. We just needed to get the live testing done. Once we had proof, the rest would follow.

And it looked like it would.

Large pharmaceutical companies were interested. An airline wanted to give the masks to its elite flyers—price wasn't an issue. State governments reached out.

I was concerned we wouldn't have enough UVC LEDs. I called the manufacturer and asked how quickly they could ramp up production.

They said they had the capacity.

We even discussed contingencies. If there was a shortage, would only first responders get them? We were planning for scale. For deployment. For real use.

No urgency. No pivot. No reckoning.

Filtration was still the answer everyone wanted. It fit existing systems. It didn't require rethinking infrastructure or responsibility. It didn't ask people to change.

Don and I had spent two years pushing an idea to proof. But there was a mandate for filtration. Companies and governments didn't want to go against it—not because the technology didn't work, but because the regulatory framework had already locked in on filtration. No one wanted to be the outlier.

Being right wasn't enough.

I couldn't shake the feeling that the filtration mandate had more to do with managing fear than managing risk. But by then, it didn't matter what I thought.

Later, studies would show cloth masks and bandanas offered minimal protection. But by then, the messaging had set. The infrastructure was built around filtration. Changing course would have meant admitting uncertainty—and no one wanted to do that during a crisis.

I didn't feel angry. I felt empty.

The work hadn't failed. It simply hadn't mattered. And I was out of reserve.

What stayed with me wasn't just the loss. It was the realization that no one was thinking about the next pandemic. We had proof of a solution that could interrupt transmission—not just filter it—and the world chose to move on.

I had been sick. Then sicker. Then functional. Now I was just tired.

Not the kind of tired that sleep fixes. The kind that tells you something inside has reached its limit.

For the first time, stopping wasn't a decision. It was a necessity.

‍

‍